Clinical Trial

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi- centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients over the age of 65 years.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-04-29; most recent amendment 2025-11-12.
Status change: Recruiting → Active, Not Recruiting 2025-11-12
Status change: Not Yet Recruiting → Recruiting 2022-05-27
Trial Details
NCT Number NCT05360732
Lead Sponsor Fox Chase Cancer Center
Conditions Metastatic Pancreatic Cancer
Enrollment 37 participants
Start Date 2022-04-22
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-13